TY - JOUR
T1 - Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment
AU - Schoot, Reineke A.
AU - Slater, Olga
AU - Ronckers, C. cile M.
AU - Zwinderman, Aeilko H.
AU - Balm, Alfons J. M.
AU - Hartley, Benjamin
AU - van den Brekel, Michiel W.
AU - Gupta, Sanjeev
AU - Saeed, Peerooz
AU - Gajdosova, Eva
AU - Pieters, Bradley R.
AU - Gaze, Mark N.
AU - Mandeville, Henry C.
AU - Fajardo, Raquel Davila
AU - Chang, Yen Ch'ing
AU - Gains, Jennifer E.
AU - Strackee, Simon D.
AU - Dunaway, David
AU - Abela, Christopher
AU - Mason, Carol
AU - Smeele, Ludi E.
AU - Chisholm, Julia C.
AU - Levitt, Gill A.
AU - Kremer, Leontien C. M.
AU - Grootenhuis, Martha A.
AU - Maurice-Stam, Heleen
AU - Stiller, Charles A.
AU - Hammond, Peter
AU - Caron, Huib N.
AU - Merks, Johannes H. M.
N1 - With supplementary data
PY - 2015/7
Y1 - 2015/7
N2 - Background: Radiotherapy is a well-known cause of adverse events (AEs). To reduce AEs, an innovative local treatment was developed in Amsterdam: Ablative surgery, MOuld brachytherapy and surgical REconstruction (AMORE). Aims: (1) to determine the prevalence of AEs in HNRMS survivors and (2) to compare AEs between survivors treated with the international standard: external beam radiotherapy (EBRT-based: London) and survivors treated with AMORE if feasible, otherwise EBRT (AMORE-based: Amsterdam). Methods: All HNRMS survivors, treated in London or Amsterdam between January 1990 and December 2010 (n = 153), and alive ≥2 years post-treatment were eligible (n = 113). A predefined list of AEs was assessed in a multidisciplinary clinic and graded according to the Common Terminology Criteria for Adverse Events. Results: Eighty HNRMS survivors attended the clinic (median follow-up 10.5 years); 63% experienced ≥1 severe or disabling event, and 76% had ≥5 AEs (any grade). Survivors with EBRT-based treatment were, after adjustment for site, age at diagnosis, and follow-up duration, at increased risk to develop any grade 3/4 event or P5 AEs (any grade) compared with survivors with AMORE-based treatments (p = 0.032 and 0.01, respectively). Five year overall survival (source population) after EBRT-based treatment was 75.0%, after AMORE-based treatment 76.9%, p = 0.56. Conclusion: This study may serve as a baseline inventory and can be used in future studies for prospective assessments of AEs following the introduction of novel local treatment modalities. AMORE-based local treatment resulted in similar overall survival and a reduction of AEs secondary to local treatment.
AB - Background: Radiotherapy is a well-known cause of adverse events (AEs). To reduce AEs, an innovative local treatment was developed in Amsterdam: Ablative surgery, MOuld brachytherapy and surgical REconstruction (AMORE). Aims: (1) to determine the prevalence of AEs in HNRMS survivors and (2) to compare AEs between survivors treated with the international standard: external beam radiotherapy (EBRT-based: London) and survivors treated with AMORE if feasible, otherwise EBRT (AMORE-based: Amsterdam). Methods: All HNRMS survivors, treated in London or Amsterdam between January 1990 and December 2010 (n = 153), and alive ≥2 years post-treatment were eligible (n = 113). A predefined list of AEs was assessed in a multidisciplinary clinic and graded according to the Common Terminology Criteria for Adverse Events. Results: Eighty HNRMS survivors attended the clinic (median follow-up 10.5 years); 63% experienced ≥1 severe or disabling event, and 76% had ≥5 AEs (any grade). Survivors with EBRT-based treatment were, after adjustment for site, age at diagnosis, and follow-up duration, at increased risk to develop any grade 3/4 event or P5 AEs (any grade) compared with survivors with AMORE-based treatments (p = 0.032 and 0.01, respectively). Five year overall survival (source population) after EBRT-based treatment was 75.0%, after AMORE-based treatment 76.9%, p = 0.56. Conclusion: This study may serve as a baseline inventory and can be used in future studies for prospective assessments of AEs following the introduction of novel local treatment modalities. AMORE-based local treatment resulted in similar overall survival and a reduction of AEs secondary to local treatment.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84934945611&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/25998323
UR - https://pure.uva.nl/ws/files/2640675/175815_514688_mmc1.docx
U2 - https://doi.org/10.1016/j.ejca.2015.02.010
DO - https://doi.org/10.1016/j.ejca.2015.02.010
M3 - Article
C2 - 25998323
SN - 0959-8049
VL - 51
SP - 1424
EP - 1434
JO - European journal of cancer (Oxford, England
JF - European journal of cancer (Oxford, England
IS - 11
ER -